What Healthcare Investment Banking Is and How Bankers Get Paid
Healthcare investment banking is the business of advising on the sale, purchase and financing of healthcare companies. Clients include physician, dental and ASC groups, services and technology companies, life sciences firms and health systems. On a sale or private raise, most of the banker's pay is a success fee at closing. It is a percentage of a transaction value that the engagement letter defines. The letter can add a retainer, a minimum fee, capped expenses and a tail. Underwriters earn a discount on shares sold. Fairness opinions carry a fee for the opinion itself.
The deal flow is large. The Private Equity Stakeholder Project (PESP) tracked 1,029 private equity-backed healthcare deals in calendar 2025 and calls that count likely an underestimate.
Data as of November 20, 2026. Each figure carries its source, population and period. Figures marked "our arithmetic" are calculated from those sources or from stated assumptions.
How Healthcare Investment Banking Is Organized
Large banks split the work along two axes. Coverage groups own client relationships within an industry. Product groups run the transaction. A healthcare coverage banker knows the sector, the buyers and the reimbursement model. The M&A, equity capital markets (ECM) or leveraged finance team runs the deal mechanics. Middle-market and specialist firms usually combine both roles in one team.
Healthcare has its own banking groups because of its size and its payer structure. The CMS National Health Expenditure fact sheet reports that US health spending grew 7.2% to $5.3 trillion in 2024, 18.0% of GDP. Physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024. Medicare spending grew 7.8% to $1,118.0 billion, 21% of the total. CMS projects physician and clinical services spending to grow 5.5% a year on average from 2025 to 2034. Medicare's share is why every buyer asks about payer mix. A banker who cannot explain your reimbursement exposure will misprice your business.
| Coverage group | Typical clients | What drives value | Common mandates |
|---|---|---|---|
| Providers and services | Physician, dental, ASC, home health, behavioral health, physician practice management | EBITDA quality, payer mix, provider retention, compliance history | Sell-side M&A, recapitalizations, add-on programs |
| Healthcare IT | Software, revenue cycle, data and analytics companies | Recurring revenue, retention, growth | M&A, growth equity raises |
| Medtech and devices | Device makers, diagnostics, tools | Revenue growth, FDA clearance status, reimbursement coverage | Strategic M&A, IPOs, follow-on offerings |
| Biopharma and life sciences | Drug developers, CDMOs, CROs | Pipeline value, clinical data, cash runway | IPOs, follow-ons, PIPEs, licensing and M&A |
| Hospitals and health systems | Not-for-profit and for-profit systems | Operating margin, market share, community benefit | Mergers, divestitures, fairness opinions, bond financings |
Biopharma is valued differently. Most clinical-stage biotech companies have no revenue and no EBITDA. Bankers value them on risk-adjusted net present value (rNPV). Each future cash flow is weighted by the probability the drug reaches that stage, then discounted for time.
Illustrative rNPV, our arithmetic. Every input is an assumption chosen to show the method, not a sector benchmark. A drug entering Phase 3 has post-launch cash flows worth $400,000,000 measured at approval, three years out. Assume a 50% cumulative probability of approval, a 10% discount rate and an $80,000,000 Phase 3 cost paid today.
| Step | Calculation | Value |
|---|---|---|
| Risk-weighted value at approval | $400,000,000 × 50% | $200,000,000 |
| Discounted to today | $200,000,000 ÷ 1.10³ (1.331) | about $150,263,000 |
| Phase 3 cost, paid today | ($80,000,000) | |
| rNPV | about $70,263,000 |
Cut the approval probability to 40% and rNPV falls to about $40,210,000 ($160,000,000 ÷ 1.331, less $80,000,000). A 10-point change in one input moves value by about $30 million. That is why biotech financings cluster around clinical readouts. Companies raise through IPOs, follow-on offerings, PIPEs (private investments in public equity) and at-the-market programs. Biopharma M&A often uses contingent value rights or milestone payments. They close a price gap the same way an earnout does in a practice sale.
Geography matters. US physician-group consolidation has no close European equivalent. Bain & Company's Global Healthcare Private Equity Report 2026 finds that investment in scale physician groups is far less common in Europe because national markets and regulation are fragmented.
Firm Tiers and Who Staffs Your Deal
An owner selling a $12,000,000 practice and a public company raising $200,000,000 hire from different tiers. The names are examples of each tier, not a ranking.
| Firm tier | Examples with healthcare practices | Typical healthcare work |
|---|---|---|
| Bulge bracket | Goldman Sachs, J.P. Morgan, Morgan Stanley, BofA Securities | Large-cap strategic M&A, IPOs, leveraged finance for sponsor buyouts |
| Elite boutique | Centerview Partners, Evercore, PJT Partners | Advice on large pharma and medtech M&A, restructuring |
| Healthcare specialist | Leerink Partners (biopharma and medtech), Cain Brothers at KeyBanc Capital Markets (providers and systems), Ziegler (not-for-profit systems and senior living) | Sector-only M&A, ECM and tax-exempt financing |
| Middle market | Harris Williams, William Blair, Houlihan Lokey, Lincoln International | Sales of provider, services and health IT platforms to sponsors and strategics |
| Lower middle market and practice specialists | Regional and specialty-focused firms | Physician, dental and ASC sales, often as add-ons to existing platforms |
| Title | Day-to-day work on your deal | What the role is judged on |
|---|---|---|
| Analyst | Models, comparable transaction sets, data room, first drafts of the confidential information memorandum (CIM) | Accuracy and speed |
| Associate | Owns the model and CIM, manages analysts, runs diligence calls | Execution without errors |
| Vice president | Runs the process day to day, manages buyer contact and the timeline | Getting signed deals to closing |
| Director | Leads smaller mandates, builds coverage relationships | Mandates won and executed |
| Managing director | Owns client and sponsor relationships, sets price strategy, negotiates key terms | Fees generated |
The managing director who pitches may spend little time on your deal. The analyst building your model may be in their first year. Ask who staffs the deal, how many active mandates each person carries and how many hours the managing director will commit.
Who Hires a Healthcare Banker and for What
| Your goal | Mandate | What the banker does | Usual pay trigger |
|---|---|---|---|
| Sell a practice or company | Sell-side M&A | Prepares financials and the CIM, builds the buyer list, runs bidding, negotiates the letter of intent | Closing of the sale |
| Buy practices as a platform or group | Buy-side M&A | Finds and screens targets, supports diligence and financing | Closing of a purchase |
| Sell a majority stake and keep equity | Recapitalization | Runs a sale process with structured rollover | Closing |
| Raise growth or minority capital | Private placement | Places securities with investors | Closing of the funding |
| Raise public equity | ECM underwriting | Prices and sells shares in an IPO or follow-on | Underwriting discount, deducted from proceeds at settlement |
| Get board approval of a price | Fairness opinion | Written view on whether the price is fair from a financial point of view | Delivery of the opinion |
Small buy-side deals often do not need a banker's financing network. A physician buying a single practice can look at the SBA 7(a) loan program, the SBA's main small business loan program. The program sets a loan limit that can change, so confirm the current rule with the lender. The sell-side vs buy-side guide explains who each advisor represents.
Look up the firm and each banker on FINRA BrokerCheck before you sign. It is free and shows registration and disclosure history. The guide to choosing a healthcare investment banker covers the rest of the vetting.
How Bankers Get Paid: Retainers, Success Fees and Fee Scales
A fee letter pairs a small guaranteed payment, if any, with a larger payment that depends on closing. For each clause, ask who carries the risk if the deal fails or closes at a low price. Every term is negotiable.
| Fee component | What it pays for | When it is owed | Question to ask |
|---|---|---|---|
| Retainer | Early work on financials, materials and outreach | Upfront or monthly, whether or not a deal closes | Is it credited in full against the success fee? |
| Success fee | The completed transaction | At closing, unless you negotiate a deferral | Is the rate flat, declining by band, or rising above a target price? |
| Minimum fee | A floor on the banker's pay | At closing, if the formula falls below it | At what price does the formula overtake the minimum? |
| Expenses | Travel, data room, databases, the banker's own counsel | Monthly or at closing, often even with no deal | Is there a hard cap, with approval needed above it? |
| Tail | Protection for buyers the banker introduced | If you close with a listed buyer within the tail period after termination | Will you attach a named buyer list at termination? |
| Exclusivity | The banker's sole right to run the process | Full engagement term | Are buyers we bring ourselves carved out? |
| Transaction value | The base the success fee is calculated on | Fixed at signing, applied at closing | Are rollover, earnouts and assumed debt included, and is the fee on contingent pieces paid only as earned? |
Three rate shapes and what each rewards:
| Shape | How it works | What it rewards |
|---|---|---|
| Flat rate | One percentage on the whole base | Closing, with price rewarded in proportion |
| Flat rate plus incentive | Higher percentage on value above a target price | Price above your walk-away number |
| Declining scale (Lehman-style) | Higher percentage on the first band, lower percentages above it | Closing more than price |
Negotiating checklist:
- Retainer. Require full credit against the success fee. Otherwise it adds to your cost even when the sale closes.
- Minimum fee. Divide the minimum by the rate to find the crossover price. Below it, the banker earns the same amount whatever the price.
- Expenses. Set a hard cap and require written approval above it.
- Tail. Limit it to buyers on a written list of parties the banker actually contacted.
- Exclusivity. Carve out deals you source yourself, such as a buyout by your partners or a hospital that called you directly.
- Transaction value. Exclude or discount rollover. Pay the fee on earnouts and seller notes only when they pay.
- Conflicts. Ask in writing whether the banker or the firm represents, or is paid by, any likely bidder.
Compare letters line by line. Fee letters are private contracts. No public dataset reports healthcare fee rates or how often retainers appear, so your own comparison is the benchmark. Get a draft letter from every banker you interview and fill in seven lines for each:
| Line | Banker A | Banker B | Banker C |
|---|---|---|---|
| Rate at your likely price | |||
| Minimum fee | |||
| Crossover price (minimum ÷ rate) | |||
| Retainer and credit | |||
| Expense cap | |||
| Tail length and buyer list | |||
| What transaction value includes |
Worked Example: Reading a Fee Letter for a Dermatology Group Sale
Our arithmetic. Fee terms are assumptions for illustration, not market rates. A dermatology group sells to a private equity platform for a headline enterprise value of $12,000,000. That is $8,000,000 cash at closing, $3,000,000 rollover equity and a $1,000,000 earnout at face value. There is no assumed debt and no working capital adjustment. The letter sets a 3% flat success fee, a $300,000 minimum fee, a $50,000 retainer credited against the success fee and a $40,000 expense cap. Expenses reach the cap. All costs are measured against the $8,000,000 of closing cash, before taxes.
| Line | Broad base (cash + rollover + earnout) | Cash-only base |
|---|---|---|
| Fee base | $12,000,000 | $8,000,000 |
| Formula fee (3% × base) | $360,000 | $240,000 |
| Success fee payable (greater of formula fee or $300,000 minimum) | $360,000 (formula governs) | $300,000 (minimum governs) |
| Retainer paid at signing, credited | $50,000 | $50,000 |
| Success fee balance paid at closing | $310,000 | $250,000 |
| Expenses at cap | $40,000 | $40,000 |
| Total banker cost | $400,000 | $340,000 |
| Total cost as share of closing cash | 5.0% | 4.25% |
| Closing cash less total banker cost | $7,600,000 | $7,660,000 |
What the table shows:
- The minimum can switch off the incentive. Under the cash-only base, the formula overtakes the minimum only once cash passes $10,000,000 ($300,000 ÷ 3%). Below that, the banker's pay is flat. Pair a cash-only base with a lower minimum, or the banker has no fee reason to push the cash price.
- You pay cash on rollover. Under the broad base, $90,000 of the fee (3% × $3,000,000) is charged on equity you cannot sell until a later recapitalization or sale. It comes out of your closing cash. Test the stake in the rollover equity calculator.
- Earnout timing. Under the broad base, you pay $30,000 at closing on the earnout (3% × $1,000,000). SRS Acquiom's 2026 M&A Earnout and Milestone Trends study reports a median of 43 cents on the dollar for lower middle-market earnouts with any payout. That median leaves out earnouts that paid nothing, so it describes size of payout, not odds of payment. If this earnout paid at the median ($430,000), a fee paid as earned would be $12,900, which is $17,100 less than paying at closing. If it pays nothing, the $30,000 bought nothing. The earnout value calculator lets you apply your own probability of payment.
- No retainer credit. Total cost rises by $50,000 in each column, to $450,000 and $390,000.
- Break-even, as a decision rule. The cash-only letter costs $340,000, or 4.25% of closing cash. In cash terms, the banker pays for themselves only if a competitive process lifts closing cash by more than that over what you would have accepted alone. Better rollover, earnout or employment terms can also justify the cost, but put a number on each.
Ranking Two Bids on Certain Cash
A letter of intent fixes the shape of the deal, and leverage drops once you sign it and grant exclusivity. Rank bids on certain cash first and headline second. Our arithmetic, same fee letter as above. Bid B's other $1,500,000 is rollover.
| Line | Bid A | Bid B |
|---|---|---|
| Headline value | $12,000,000 | $11,000,000 |
| Cash at closing | $8,000,000 | $9,500,000 |
| Rollover equity | $3,000,000 | $1,500,000 |
| Earnout at face | $1,000,000 | $0 |
| Banker cost, cash-only base (fee + expenses) | $340,000 ($300,000 minimum governs) | $340,000 ($285,000 formula fee, so $300,000 minimum governs) |
| Net closing cash, cash-only base | $7,660,000 | $9,160,000 |
| Banker cost, broad base | $400,000 | $370,000 ($330,000 + $40,000) |
| Net closing cash, broad base | $7,600,000 | $9,130,000 |
Bid B delivers about $1,500,000 more certain cash under either base. Bid A wins only if its extra $1,500,000 of rollover plus the $1,000,000 earnout are worth more than that to you today. At the SRS median for earnouts with any payout, the earnout is worth $430,000 if it pays at all. The rollover's value depends on the platform's debt and hold period. Bid A's headline is $1,000,000 higher, but in this example its certain value after banker cost is about 63% to 64% of headline ($7,600,000 to $7,660,000 of $12,000,000).
What to have in hand before you sign a letter of intent:
- A one-page summary of each bid, restated as cash at closing, rollover, earnout and seller note.
- Your walk-away cash number, set before you see the bids.
- The fee letter's cost at each bid, run through the deal proceeds calculator.
- Your own earnout value from the earnout value calculator, using targets tied to metrics your group controls.
- Written answers from the buyer on its debt, hold period, rollover terms and plans for your physicians.
- An after-tax comparison of the bids from your tax adviser.
Headline Value vs. Realized Value
Bankers argue that a fee based on value aligns their interests with yours. That holds for the headline number and is weaker for terms. A banker paid on headline value gains nothing from moving value toward cash at closing and away from rollover and earnouts you may never collect.
Earnout payout depends heavily on deal size. Both figures come from the same SRS Acquiom 2026 study and cover earnouts with any payout:
| Deal population (SRS Acquiom, 2026 study) | Median paid per dollar of earnout |
|---|---|
| Lower middle-market deals | 43 cents |
| Deals with more than $50 million upfront | 67 cents |
For a practice sale, treat an earnout's face value as a ceiling.
Buyer mix moves price too. One sell-side firm, FOCUS Investment Banking, states in its Healthcare EBITDA Multiples: 2026 Dashboard that corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. That is an advisor's read of its market, not a transaction database. Its practical point holds: a process that adds a credible corporate buyer can change the price range. The valuation multiples guide and practice valuation calculator show how private values are built.
Where Banker Mandates Come From: PESP's 2025 Count
PESP's Private Equity Healthcare Deals: 2025 in Review counted 1,029 private equity-backed deals in calendar 2025, involving 420 platform companies and 708 investment firms. It draws on PitchBook and LevinPro HC, covers sponsor-backed deals only and calls its count likely an underestimate.
| Deal type, 2025 (PESP) | Count | Share of 1,029 (our arithmetic) | Usual counterparty |
|---|---|---|---|
| Add-on acquisitions | 664 | 64.5% | A PE-owned platform buying a practice or company |
| Growth investments | 214 | 20.8% | A sponsor buying a minority or structured stake |
| Leveraged buyouts | 151 | 14.7% | A sponsor buying control, often creating a platform |
By our arithmetic, add-ons outnumbered buyouts about 4.4 to 1 (664 ÷ 151) and averaged about 1.6 per platform (664 ÷ 420). The average hides concentration. PESP reports that ten of the 18 platforms with the most 2025 deals were dental companies, and 95% of the 149 dental deals were add-ons by PE-owned platforms.
| Most active subsector, 2025 (PESP) | PE deals | What it signals for sellers |
|---|---|---|
| Health IT | 151 | Software and services buyers, valued on recurring revenue |
| Dental care | 149 | Dense platform buying, almost all as add-ons |
| Outpatient care | 148 | Specialty physician groups, mostly sold as add-ons |
| Medtech | 117 | Strategic and financial buyers competing |
| Behavioral health | 56 | Fewer deals, closer scrutiny of payer and licensing risk |
Health IT's 151 deals and the 151 buyouts are separate figures. One groups deals by subsector, the other by deal type.
Decision rule for a practice owner. Buying practices is a platform's core business, so many owners hear directly from a platform's corporate development team. Estimate the banker's total cost. Then ask whether a competitive process can lift closing cash by more than that. If the banker cannot name several platforms in your specialty that closed add-ons in the past 12 months, the answer is probably no.
Outpatient Specialties: Dermatology, Eye Care, Oncology
PESP data reported by Becker's ASC Review shows 148 private equity-backed outpatient care deals in calendar 2025, 119 of them add-ons.
| Outpatient subsector, 2025 (PESP via Becker's ASC Review) | PE deals |
|---|---|
| Dermatology | 24 |
| Eye care | 22 |
| Oncology | 9 |
| All outpatient care | 148 (119 add-ons) |
Add-ons were about 80% of outpatient deals (119 ÷ 148, our arithmetic). A dermatologist or ophthalmologist selling today will most likely sell to an existing platform. The banker earns the fee by getting several platforms to bid against each other. The 24 dermatology deals are a national count, so ask how many platforms are buying in your state and which of them the banker has closed with. Ask for the deals the proposed team closed in your specialty over three years. A pitch book full of hospital and medtech tombstones says little about a dermatology sale. The physician roll-ups guide explains how platforms are built.
Hospital and Health System M&A in 2026
The quarterly counts below are Kaufman Hall figures as reported by Becker's Hospital Review after the Q3 2026 report. Earlier quarters reflect counts as of that report.
| Period | Announced hospital transactions (Kaufman Hall) | Average per quarter (our arithmetic) |
|---|---|---|
| Full year 2025 | 46 | 11.5 |
| Q1 2026 | 22 | |
| Q2 2026 | 18 | |
| Q3 2026 | 16 | |
| 2026 through Q3 | 56 | about 18.7 |
The 2025 total was the lowest annual count since Kaufman Hall began tracking hospital transactions in 2011, so part of 2026's rise is recovery from a low base. The count also fell each quarter of 2026.
Kaufman Hall's Q3 2026 release, dated October 13, 2026, adds detail on the quarter. Kaufman Hall defines a mega merger as a deal in which the smaller party has more than $1 billion in annual revenue, per Becker's Hospital Review.
| Q3 2026 measure (Kaufman Hall) | Figure |
|---|---|
| Transactions announced | 16, matching Q3 2025 |
| Total transacted revenue | $8.2 billion |
| Average seller size | Approaching $586 million in annual revenue |
| Mega mergers | 2, the third straight quarter with deals of that size |
| Most common acquirer | Not-for-profit organizations |
| Divestitures | Nearly one-third of announced deals |
The release says 2026 could become a record year for transactions in which the smaller party has more than $1 billion in annual revenue. That is a record for the mega merger category, not for overall deal count.
Financial pressure. The same release puts hospital year-to-date operating margin at 2.5% including allocations, with nearly 43% of hospitals operating at a loss, on data through August 2026. Non-labor expenses rose 6% year-to-date per adjusted discharge against 2025, with supply expenses up 5% and drug expenses up 6%. Our read: margins that thin push systems toward scale mergers and sales of non-core assets, which fits the mega merger and divestiture figures.
For physician groups and platforms. With divestitures near one-third of Q3 deals, groups can buy assets systems are shedding. That is a buy-side mandate, where the advisor is paid when you buy. Ask how the fee changes if you walk away from an overpriced asset. System boards follow a longer process with fairness opinions, covered in the healthcare M&A process guide.
Structure Decisions to Settle Before Your Banker Goes to Market
Structure decides which buyers can close and how consideration can be paid. A banker who has closed physician deals should be able to explain how structure changed the outcome of their last three deals in your specialty. Settle these before the CIM goes out, when changing them costs nothing.
| Decision | Options to compare | How it moves your outcome | Settle by |
|---|---|---|---|
| Sale form | Sale of assets or sale of equity | Changes after-tax proceeds, which liabilities stay with you and which payer contracts need consent | Before the CIM |
| Ownership path | Buyer owns the practice outright, or works through a management services arrangement | Changes what you sell, what you keep and how post-closing income reaches you | Before the buyer list is final |
| Consideration mix | Cash, rollover, earnout, seller note | In the bid comparison above, $1,500,000 of rollover traded for cash raised certain value by about $1,500,000 | Letter of intent |
| Physician roles after closing | Compensation model, term, restrictive covenants | Drives provider retention, which buyers price directly | Letter of intent |
| Physician co-investors | Which partners roll equity or invest alongside the sponsor | Shapes the cap table and who must approve the deal | Before the CIM |
| Buyer size and market overlap | Local platform, national platform or health system | Larger or overlapping buyers can lengthen the time from signing to closing | Buyer list |
Preparation checklist:
- After-tax comparison. Have your tax adviser model asset and equity sale proceeds at your expected price. Give the result to your banker before outreach.
- Ownership map. List every owner, their percentage and whether they will sell, roll or retire. Disagreements found during diligence cost leverage.
- Payer contracts. Pull every contract and note its term, renewal date and assignment language.
- Provider agreements. Collect each physician's and advanced practitioner's employment terms so buyers can price retention.
- Billing review. Expect buyers to compare your billing patterns with specialty norms and reconcile payer contracts with reported revenue. Fix or disclose issues before the CIM.
Regulatory areas that shape structure. Physician rollover, earnouts, post-closing pay and management services arrangements can raise questions under federal referral and self-referral rules (HHS OIG overview). State rules can limit whether a non-physician buyer can own a practice. Some deals require federal antitrust filings (FTC premerger program), and some states require notice or review of healthcare transactions. Success fees on capital raises raise broker-dealer and securities questions. These rules vary and change, so have your own attorney review each area before you sign a letter of intent. The High-risk area pages on this site, the healthcare compliance due diligence guide and the management services organizations guide cover what buyers test.
Sell-Side, Buy-Side or Capital Raise: How Each Role Is Paid
Everyone involved in your deal should be able to say plainly who pays them and what triggers payment.
| Role | Who usually pays | What triggers pay | Where conflicts arise |
|---|---|---|---|
| Sell-side banker | Seller | Closing of a sale | Speed and headline price over terms, and the minimum fee on small deals |
| Buy-side banker | Acquirer | Closing of an acquisition | Paid when the client buys, even at a full price |
| Placement agent | Company raising capital | Closing of the funding | Pay tied to amount raised can favor more capital over better terms |
| Underwriter | Issuer, through the underwriting discount | Deducted from proceeds at settlement | Pricing that clears the book versus pricing that maximizes proceeds |
| Direct-investing family office | Nobody on your side, it invests its own money | Its own return | It is your counterparty, not your advisor |
PESP counted 708 investment firms in 2025 private equity-backed healthcare deals, without separating firms investing their own capital from those managing outside money. Ask at the first meeting. A family office investing its own money negotiates for its own return, and some family offices retain bankers to find targets. If a banker calls with a buyer for your practice, ask who pays the banker. The reverse due diligence guide covers how to vet that buyer, and the physician investors guide covers partners who invest alongside a sponsor.
Vetting Advisors, Buyers and Investors
| Check | What a strong answer looks like | Red flag |
|---|---|---|
| Team | You meet the VP and associate who will write the CIM and call buyers | Only the pitching partner shows up |
| Specialty record | Named closed deals in your specialty in the past three years | Tombstones from unrelated subsectors |
| Buyer list | Platforms that closed add-ons in your specialty in the past 12 months, with reasons each fits | A database pull with no rationale |
| Selectivity | The firm declines engagements and can say why yours fits | Signs anyone who pays a retainer |
| Valuation talk | Asks about partners, payer contracts and post-sale plans first | Quotes a multiple in the first call |
| Registration | Firm and bankers appear on FINRA BrokerCheck with a clean disclosure record | No record and a percentage fee |
| Investor history | Form D notices on SEC EDGAR full-text search match the private raises the investor or platform describes | Claimed raises with no filing trail |
| Rollover partner | The platform shares its debt load, the sponsor's hold period and exit plan, and the terms of your rollover units | Rollover terms promised "later" |
If a well-regarded banker turns you down, ask what would change the answer. That is a free readiness check. The guide to preparing a healthcare company for sale covers the fixes.
A Career in Healthcare Investment Banking
Many people searching this topic want to work in the field. The structure is consistent across firms.
| Step | What happens | What to have ready |
|---|---|---|
| 1. Early networking | Calls and coffee chats with analysts and associates in target groups | A clear reason for healthcare, such as a clinical, science or hospital finance background |
| 2. Internship recruiting | Large banks fill summer analyst and summer associate classes well before the internship begins | Accounting, valuation and a working three-statement model |
| 3. The internship | A summer of live deal work, judged for a return offer | Accuracy, speed, sector reading |
| 4. Full-time offer | Most full-time seats at large banks go to returning interns | Group preference, ranked |
| 5. Off-cycle or lateral entry | Boutiques, middle-market firms and lateral hires fill gaps year-round | Sector expertise a generalist lacks |
| Stage | How people enter | What the group looks for |
|---|---|---|
| Analyst | Undergraduate summer analyst internship, converted to a full-time offer | Modeling, accounting, interest in healthcare economics |
| Associate | MBA summer associate role, promotion from analyst, or direct hire of PhDs and MDs into biopharma teams | Execution, client writing, sector judgment |
| Lateral hire | Healthcare consulting, hospital finance, transaction services, corporate development | Reimbursement, payer contract and physician compensation knowledge |
| VP to MD | Internal promotion or lateral move with client relationships | Mandates won and fees generated |
What differs by group. Provider teams want people who read payer mix, physician compensation and add-on economics. Biopharma teams value clinical judgment because probabilities drive valuation, as the rNPV example shows. Health IT teams work like software bankers with a reimbursement overlay. Hospital teams run longer, board-driven processes and tax-exempt financings. Provider bankers also track sector labor costs, and the BLS Health Care and Social Assistance industry page is the official source for current employment and wage figures.
How pay works. Compensation is a base salary plus a discretionary bonus. The bonus grows as a share of total pay with seniority, and at managing director level it tracks the fees the banker generates. Firm tier, deal volume and the year's fee pool move bonuses more than title does. No government dataset reports banker pay by healthcare group. The ranges candidates quote come from recruiter and industry surveys, which differ by sample and firm tier. Ask current analysts at your target firms what their class was paid.
How to read league tables. LSEG, Dealogic, PitchBook and Mergermarket publish healthcare advisor rankings by deal count and disclosed value. Each advisor on a deal generally receives full credit, so a co-advisor role counts the same as leading the deal. Value rankings favor banks on a few very large pharma mergers. Count rankings favor middle-market firms that close many provider deals with undisclosed prices. A candidate choosing a provider group, and an owner choosing a banker, should look at deal count in the specialty, not total value.
Where bankers go next. Common exits are healthcare private equity, growth equity, corporate development at sponsor-backed platforms and health systems, and pharma business development. The buy-side employer pool is large. PESP counted 708 investment firms and 420 platform companies in 2025 private equity healthcare deals, and each platform running an add-on program needs people who can source, model and close acquisitions.
One implication for sellers. The VP running your process may later join a buyer you will meet again. Bankers who work across the table from the same sponsors for years have reason to run clean processes, and reason to avoid antagonizing frequent buyers. Ask how many of your likely bidders the firm has sold to in the past two years.
Questions Practice Owners, Investors and Candidates Ask
What does a healthcare investment banker do?
A healthcare investment banker advises physician groups, dental and ASC owners, services and technology companies, life sciences companies and health systems on selling, buying and raising capital. At large banks, a healthcare coverage group owns client relationships and product groups run the M&A, equity and debt work. In the middle market, one specialist team usually does both. Sell-side and capital-raising bankers earn most of their pay from a success fee owed at closing.
How do people get into healthcare investment banking?
The main entry points are an undergraduate summer analyst internship that converts to a full-time analyst offer, and an MBA summer associate role that converts to a full-time associate offer. Healthcare groups also hire laterally from healthcare consulting, hospital finance and transaction services, and biopharma teams recruit PhDs and MDs. Pay is a base salary plus a discretionary bonus that grows as a share of total pay with seniority. Common exits are healthcare private equity, growth equity, corporate development and pharma business development.
How many healthcare M&A deals happen each year?
No single public count covers all of healthcare M&A. PESP tracked 1,029 private equity-backed healthcare deals in calendar 2025: 664 add-on acquisitions, 214 growth investments and 151 leveraged buyouts. PESP calls its count likely an underestimate, and it covers sponsor-backed deals only. Kaufman Hall separately counted 46 hospital and health system transactions in 2025, as reported by Becker's Hospital Review. The two counts cover different markets and should not be added together.
Is hospital and health system M&A picking up in 2026?
Yes, by volume. Kaufman Hall counted 56 announced hospital transactions through Q3 2026, as reported by Becker's Hospital Review, against 46 in all of 2025. By our arithmetic that is about 18.7 per quarter in 2026 against 11.5 in 2025. The quarterly count fell during the year, from 22 in Q1 to 18 in Q2 and 16 in Q3. Kaufman Hall's October 13, 2026 release says 2026 could become a record year for deals in which the smaller party has more than $1 billion in annual revenue.
Which medical specialties are private equity buyers acquiring most?
Of 148 private equity-backed outpatient care deals in 2025, dermatology led with 24, eye care had 22 and oncology had 9, according to PESP data reported by Becker's ASC Review. 119 of the 148 were add-ons. PESP tracks dental care separately and logged 149 deals there in 2025, 95% of them add-ons by PE-owned platforms.
Do bankers charge a success fee on rollover equity and earnouts?
That depends on how the fee letter defines transaction value. A broad definition counts rollover equity, earnouts, assumed debt and seller notes, and each one raises the fee base. SRS Acquiom's 2026 study found that lower middle-market earnouts that paid anything paid a median of 43 cents on the dollar. Many sellers negotiate to pay the earnout portion of the fee only as the earnout pays. Settle the definition before signing the engagement letter.
Sources
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review, calendar 2025 private equity-backed deals, PitchBook and LevinPro HC data
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity, PESP 2025 outpatient data
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report release, October 13, 2026, announced hospital and health system transactions, with year-to-date margin and expense data through August 2026
- Becker's Hospital Review, Hospital M&A on pace for busiest year since pandemic as megamergers mount, Kaufman Hall quarterly counts through Q3 2026, the 2025 total and the mega merger definition
- CMS, National Health Expenditure fact sheet, 2024 spending and 2025 to 2034 projections
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends, earnout payout medians for earnouts with any payout
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard, published by a sell-side advisory firm
- Bain & Company, New Models of Value Creation for Physician Groups, Global Healthcare Private Equity Report 2026
- HHS OIG, A Roadmap for New Physicians: Fraud and Abuse Laws
- Federal Trade Commission, Premerger Notification Program
- U.S. Small Business Administration, 7(a) loans
- SEC EDGAR full-text search, including Form D notices
- FINRA BrokerCheck, registration lookup for firms and individuals
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance